Results highlighted by 92% increase in Adjusted EBITDA, 18% increase in revenue MISSISSAUGA, ON, May 11, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Health Canada approval of OZANEX™ (ozenoxacin cream, 1%) a novel topical antibiotic indicated for the treatment of impetigo in patients...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it has completed an agreement (the "Agreement") to sell substantially all of the assets of Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2017 financial results conference call and Annual Meeting of shareholders on Thursday, May...

Mark Beaudet expected to be appointed new independent Chair of Board MISSISSAUGA, ON, April 12, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced...